Test of different myocardial
biomarkers is commonly arranged in patients with
aneurysmal subarachnoid hemorrhage (aSAH). We sought to figure out whether different myocardial
biomarkers' elevation is related to characteristics of
ruptured aneurysms and patients' clinical outcomes. Patients with aSAH admitted in the Neurosurgery Department of West China Hospital from September 2019 to March 2020 were screened. Those who have one clear responsible
aneurysm and met inclusion criteria were included. Clinical characteristics, site and size of the
aneurysm, modified Fisher scale,
troponin T (TPN-T),
creatine kinase MB (CK-MB), and
myoglobin (Myo) levels at admission, clinical outcomes (3-month mRS) were collected and compared. The study included 124 patients. After multivariate logistic regression, Hunt & Hess grade (per unit grade, OR 1.68, 95% CI 1.14-2.49), the size of
ruptured aneurysm (equal to or more than 7 mm, OR 3.07, 95% CI 1.32-7.10) was highly predictive of myocardial
biomarker elevation. All three
biomarkers (TPN-T, CK-MB, Myo) were associated with unfavorable prognoses. Higher mortality (37.2% vs. 18.6%, P = 0.036) and a lower rate of good outcomes (41.9% vs. 71.2%, P = 0.003) were observed in patients with any positive myocardial
biomarkers at admission. The clinical outcomes of patients with positive
troponin T and negative
creatine kinase MB were especially unfavorable. Our study demonstrates that the degree of neurological injury and size of
ruptured aneurysm are strong predictors of myocardial
biomarkers elevation, the site of
ruptured aneurysm may not be associated with
heart injury after SAH. The outcomes of patients with different combinations of abnormal
biomarker levels may have significant differences and deserve further study.